Naturopathic doctor Joanne Elphinstone is best known for her work treating people with cancer.
But she is also known for being a passionate advocate for the use of naturopathy in other fields.
So when she heard that the US Food and Drug Administration (FDA) had issued a warning that naturopaths could be at risk for developing an inflammatory condition called non-Hodgkin lymphoma (NHL), she decided to take a look.
Ms Elphinsons research led her to a new technique she uses, which she calls “the whole body approach”.
“The whole body is a way of thinking that’s very important for how we understand disease, disease processes and how we diagnose and treat,” Ms Elphiins said.
“If you do this in your body you can get this information from your immune system in real time and get this all-important information for you to know if there’s a cancer.”
Ms Elphainsons team at the National Cancer Institute (NCI) is using a technology called a biofeedback device called a Thermo-feedback to track the immune system of people with NHL.
“If the immune response is low, you don’t have this negative feedback loop that you have to deal with and you’re not going to be able to really heal,” she said.
MsElphinstons team is testing out a new type of biofeedBACK device called the Biofeedback ThermoFeedback system.
“I’m actually starting to do a clinical trial to see how well this system works in people with this condition,” MsElphiins explained.
“We’re trying to get the biofeed back in a way that allows the immune to get all the information it needs to treat the disease.”
The technology is based on the use, and in some cases the regulation, of a drug known as a biologic, or a biological drug.
This drug is known as Rituxan.
The drug was developed to treat Crohn’s disease and other inflammatory bowel diseases, and it has shown promising results.
Nanomedicine is a new area of research where scientists are looking at how to use biologic drugs to treat cancer.
The idea is to treat people with the drug with the right combination of drugs, and then use this information to make a decision on which treatment is best for them.
When it comes to treating NHL, Dr Elphiinson’s team is taking the whole body method to its logical conclusion.
It works like this: MsElphains first tries to identify which of the symptoms of NHL are linked to the disease.
She does this by monitoring a blood test called a blood biomarker, which measures the amount of certain proteins produced in the body that can be used to identify a patient.
The more proteins that are found in the blood, the more likely a patient is to have NHL.
She then takes the biomarker measurements of these patients and tries to predict how long it will take them to develop NHL.
The team also measures their immune system and how well it responds to the biomarkers.
When they have a prediction, they can use that prediction to make decisions about which treatment strategy will be most effective for the patient.
The system uses the biomarkering data to guide treatment decisions, and the team is working with the FDA to develop an approved medicine for use in people who have NHL and who are immune-compromised.
But what’s more, the whole-body approach is not restricted to people with Crohn sj , it also works in the lungs, kidneys, brain and spinal cord.
Dr Elphiinds team hopes to use this technology to treat patients who are at high risk of NHL and are immune compromised.
“In terms of a disease like NHL, where we’re seeing a significant increase in new cases, it’s really important that we can do something to reduce this risk,” Dr Elphlins said.
While MsElPhinstons team is still trying to figure out exactly how to do this, the first stage of the research is to get patients to have a baseline blood test and then take a blood sample to measure the immune systems of people who are close to being NHL.